DnB Asset Management
NAMS icon

DnB Asset Management’s NewAmsterdam Pharma NAMS Stock Holding History

DnB Asset Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$681K Sell
20,090
-1,468
-7% -$48.4K ﹤0.01% 698
2026
Q1 		$690K Buy
21,558
+1,439
+7% +$46.9K ﹤0.01% 687
2025
Q4 		$706K Buy
+20,119
New +$732K ﹤0.01% 660

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

DnB Asset Management's NAMS Position: Q2 2026 in Review

DnB Asset Management reduced its NewAmsterdam Pharma (NAMS) stake by 6.8% in Q2 2026, selling an estimated $48.4K and leaving 20,090 shares worth $681K. The position accounts for ﹤0.01% of the portfolio, ranked #698.

DnB Asset Management first reported a position in NAMS in Q4 2025 and has held it in 3 quarters since. The position peaked at $706K in Q4 2025. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • DnB Asset Management held 20,090 shares of NewAmsterdam Pharma worth $681K as of Q2 2026.
  • DnB Asset Management sold 1,468 NewAmsterdam Pharma shares in Q2 2026, an estimated $48.4K.
  • NewAmsterdam Pharma made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #698 holding.
  • DnB Asset Management first reported a position in NewAmsterdam Pharma in Q4 2025 and has held it in 3 quarters since.
  • DnB Asset Management's NewAmsterdam Pharma position peaked at $706K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.